Details

Autor(en) / Beteiligte

• Byrne, Alicia B.
• Arts, Peer
• Polyak, Steven W.
• Feng, Jinghua
• Schreiber, Andreas W.
• Kassahn, Karin S.
• Hahn, Christopher N.
• Mordaunt, Dylan A.
• Fletcher, Janice M.
• Lipsett, Jillian
• Bratkovic, Drago
• Booker, Grant W.
• Smith, Nicholas J.
• Scott, Hamish S.

Titel

Identification and targeted management of a neurodegenerative disorder caused by biallelic mutations in SLC5A6

Ist Teil von

• Npj genomic medicine, 2019-11, Vol.4 (1), p.1-8, Article 28

Ort / Verlag

London: Nature Publishing Group

Erscheinungsjahr

2019

Link zum Volltext

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• Abstract We describe a sibling pair displaying an early infantile-onset, progressive neurodegenerative phenotype, with symptoms of developmental delay and epileptic encephalopathy developing from 12 to 14 months of age. Using whole exome sequencing, compound heterozygous variants were identified in SLC5A6 , which encodes the sodium-dependent multivitamin transporter (SMVT) protein. SMVT is an important transporter of the B-group vitamins biotin, pantothenate, and lipoate. The protein is ubiquitously expressed and has major roles in vitamin uptake in the digestive system, as well as transport of these vitamins across the blood–brain barrier. Pathogenicity of the identified variants was demonstrated by impaired biotin uptake of mutant SMVT. Identification of this vitamin transporter as the genetic basis of this disorder guided targeted therapeutic intervention, resulting clinically in improvement of the patient’s neurocognitive and neuromotor function. This is the second report of biallelic mutations in SLC5A6 leading to a neurodegenerative disorder due to impaired biotin, pantothenate and lipoate uptake. The genetic and phenotypic overlap of these cases confirms mutations in SLC5A6 as the genetic cause of this disease phenotype. Recognition of the genetic disorder caused by SLC5A6 mutations is essential for early diagnosis and to facilitate timely intervention by triple vitamin (biotin, pantothenate, and lipoate) replacement therapy.